

Atezolizumab IMvigor210 – Cohort 1

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Atezolizumab IMvigor210 – Cohort 1

### SCORE

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Genitourinary Cancers

Therapeutic Indication: Patients with locally advanced or metastatic UC who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression  $\geq 5\%$

Experimental Arm: Atezolizumab

Control Arm: Single arm (Phase II)

